What are the indications, recommended dosing schedule, administration guidelines, common side effects, contraindications, and management considerations for buspirone in treating generalized anxiety disorder?

Buspirone for Generalized Anxiety Disorder

Buspirone is FDA-approved for the management of generalized anxiety disorder (GAD) and short-term relief of anxiety symptoms, with particular advantages in patients requiring long-term treatment due to its lack of dependence potential, no interaction with alcohol, and absence of psychomotor impairment. 1, 2

Indications

• Primary indication: Management of GAD or short-term relief of anxiety symptoms 1
• Efficacy demonstrated in patients with symptoms lasting 1 month to over 1 year (average 6 months duration) 1
• Effective even in patients with coexisting depressive symptoms 1
• Not indicated for anxiety associated with everyday life stress 1

Dosing Schedule

Starting dose: 7.5 mg twice daily (15 mg/day total) 3

Titration: Increase by 5 mg/day every 2-3 days as tolerated 3

Target dose: 15-30 mg/day, divided into 2-3 doses 4, 3

• 15 mg twice daily (BID) is equally effective as 10 mg three times daily (TID) and may offer better compliance 4, 3
• Maximum dose: 60 mg/day 1

Onset of action: Typically 2-4 weeks; buspirone shows faster response than SSRIs in some studies, with significant improvement by week 2 5

Duration: Efficacy beyond 3-4 weeks not established in controlled trials, though 264 patients treated for 1 year showed no ill effects 1

Administration Guidelines

• Can be taken with or without food (maintain consistency) 1
• BID dosing preferred for convenience and compliance without compromising efficacy or safety 4, 3
• Periodic reassessment needed for extended use 1

Common Side Effects

Most frequent adverse events (similar between BID and TID dosing): 4, 6

• Dizziness
• Headache
• Nausea
• Nervousness
• Lightheadedness

Notable difference: Palpitations occur more frequently with BID dosing (5%) versus TID dosing (1%) 4

Amblyopia reported more with 15 mg BID regimen 3

Key safety advantages: 7, 6

• Minimal sedation
• No psychomotor impairment
• No abuse or dependence potential
• No withdrawal symptoms
• Low lethality in overdose

Contraindications

Absolute contraindications: 1

• Hypersensitivity to buspirone
• Concurrent use with MAOIs or within 14 days of MAOI discontinuation (risk of serotonin syndrome and elevated blood pressure)
• Use within 14 days before starting an MAOI
• Concurrent use with reversible MAOIs (linezolid, IV methylene blue)

Relative contraindications: 1

• Severe hepatic impairment (increased plasma levels and prolonged half-life)
• Severe renal impairment (increased plasma levels and prolonged half-life)

Management Considerations

Drug Interactions

Critical interactions: 1

• MAOIs: Absolutely contraindicated due to serotonin syndrome risk
• Warfarin: One case report of prolonged prothrombin time; monitor INR closely 1
• May displace digoxin from protein binding (clinical significance unknown) 1

Laboratory interference: 1

• Can cause false-positive results for pheochromocytoma (interferes with urinary metanephrine/catecholamine assay)
• Discontinue 48 hours before urine catecholamine collection

Special Populations

Elderly patients: 1, 5

• No dose adjustment needed based on pharmacokinetics
• Both sertraline and buspirone effective and well-tolerated in elderly GAD patients
• Buspirone showed superior anxiolytic effect at weeks 2 and 4 compared to sertraline in elderly patients 5

Pediatric patients: 1

• Safety and efficacy evaluated in ages 6-17 years
• No significant benefit over placebo at doses of 15-60 mg/day in two 6-week trials
• Plasma exposure equal to or higher than adults for identical doses
• Not recommended for pediatric GAD based on lack of efficacy

Pregnancy: Category B - use only if clearly needed 1

Nursing mothers: Avoid if clinically possible (excreted in rat milk) 1

Critical Clinical Pitfalls

Prior benzodiazepine use: 8

• Patients recently discontinued from benzodiazepines (<1 month) show reduced response to buspirone
• Higher attrition rates and more adverse events in recent benzodiazepine users
• Initiate buspirone cautiously in this population with appropriate patient education
• Remote benzodiazepine use (≥1 month prior) does not affect buspirone response

Patient expectations: 2, 8

• Educate patients about delayed onset (2-4 weeks)
• Explain lack of immediate anxiolytic effect unlike benzodiazepines
• Emphasize safety advantages for long-term use

Switching from benzodiazepines: 2

• Gradual benzodiazepine taper recommended
• Allow adequate washout period (≥1 month preferred) before expecting full buspirone response 8
• Consider overlap period with patient education about different mechanism of action

Monitoring

• Assess treatment response using standardized anxiety rating scales 1
• Monitor for adverse effects, particularly during dose titration 4
• Periodic reassessment of continued need for extended treatment 1
• No routine laboratory monitoring required unless specific concerns 1